Skip to main content

Table 1 Treatment duration, side effects, and sequelae of cCMV patients with GCV/VGCV

From: Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study

ID CMV viral load (IU/mL) Treatment duration Reduction or suspension of therapy weeks after GCV/VGCV Side effect Sensorineural hearing loss Neuro-development†
Before GCV/VGCV 6 weeks after GCV/VGCV   at birth last visit at 2 years
1 51,761  < LoD* 6 weeks None None None None No delay
2 64,649  < LoD 6 months Suspension (4 W, 6–11 W) Elevated transaminases Both ears No change Mild
3 88,674  < LoD 6 months None None Right ear No change No delay
4 150,000  < LoD 6 weeks None None None None Mild
5 87,688 5,099 3 months None None None None No delay
6 10,994 7,535 4 months Suspension (3 W, 9–11 W)
Reduction (4–8 W)
Neutropenia None None Mild
7 116,600 31,975 6 months Suspension (9–10, 12–17 W) reduction (4–8 W) Neutropenia None None Mild
8 271,309 280,000 3 months None None None None Mild
9 18,445 1250 6 weeks None None Both ears No change Mild
10 N.A§ 2149 6 weeks None None Both ears No change Mild
11 167,250 199,125 10 months Suspension (2, 6–7, 29–32 W) Neutropenia,
Elevated transaminases
Right ear No change Moderate
  1. CMV cytomegalovirus, GCV ganciclovir, VGCV valganciclovir; * < LoD (IU/): lower than limit of detection; §N.A. not available
  2. Neurodevelopment level was defined according to the developmental quotient (DQ) as follows: no delay, > 75, mild 50–75, moderate